MARKET

MIRM

MIRM

Mirum Pharmaceuticals
NASDAQ
68.48
-3.05
-4.26%
After Hours: 68.48 0 0.00% 17:01 12/05 EST
OPEN
70.00
PREV CLOSE
71.53
HIGH
70.66
LOW
68.33
VOLUME
404.05K
TURNOVER
--
52 WEEK HIGH
78.54
52 WEEK LOW
36.88
MARKET CAP
3.52B
P/E (TTM)
-79.5077
1D
5D
1M
3M
1Y
5Y
1D
Director Michael G. Grey reports disposal of common shares of Mirum Pharmaceuticals Inc
Reuters · 4d ago
MIRM Enrolls First Patient in Phase II Fragile X Syndrome Study
NASDAQ · 5d ago
Mirum Pharmaceuticals enrolls first patient in Phase 2 BLOOM study of MRM-3379
TipRanks · 6d ago
Mirum Pharmaceuticals Enrolls First Participant Enrollment In Bloom Phase 2 Study Evaluating MRM-3379 For Fragile X Syndrome
Benzinga · 6d ago
Mirum Pharmaceuticals Begins Phase 2 Trial of MRM-3379 for Fragile X Syndrome
Reuters · 6d ago
MIRUM PHARMACEUTICALS INC - TOP-LINE DATA FROM BLOOM PHASE 2 STUDY EXPECTED IN 2027
Reuters · 6d ago
Weekly Report: what happened at MIRM last week (1124-1128)?
Weekly Report · 6d ago
Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome
Barchart · 6d ago
More
About MIRM
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the treatment of rare diseases affecting children and adults. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal or Ctexli (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. The Company is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.

Webull offers Mirum Pharmaceuticals Inc stock information, including NASDAQ: MIRM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MIRM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MIRM stock methods without spending real money on the virtual paper trading platform.